The hardware and bandwidth for this mirror is donated by METANET, the Webhosting and Full Service-Cloud Provider.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]metanet.ch.
Meta-analysis approaches for Phase I dose finding early phases clinical trials in order to better suit requirements in terms of maximum tolerated dose (MTD) and maximal dose regimen (MDR). This package has currently three different approaches: (a) an approach proposed by Zohar et al, 2011, <doi:10.1002/sim.4121> (denoted as ZKO), (b) the Variance Weighted pooling analysis (called VarWT) and (c) the Random Effects Model Based (REMB) algorithm, where user can input his/her own model based approach or use the existing random effect logistic regression model (named as glimem) through the 'dfmeta' package.
Version: | 1.0.0 |
Depends: | R (≥ 3.0.2), lme4, stats4, plyr, data.table |
Imports: | ggplot2 (≥ 2.0.0), methods, graphics, grDevices, stats, utils |
Published: | 2018-03-27 |
DOI: | 10.32614/CRAN.package.dfmeta |
Author: | Artemis Toumazi, Sarah Zohar, Anand N. Vidyashankar, Jie Xu and Moreno Ursino |
Maintainer: | Artemis Toumazi <artemis.toumazi at gmail.com> |
BugReports: | http://github.com/artemis-toumazi/dfmeta/issues |
License: | GPL (≥ 3) | file LICENSE |
URL: | http://github.com/artemis-toumazi/dfmeta |
NeedsCompilation: | no |
SystemRequirements: | C++11 |
Materials: | README |
In views: | MetaAnalysis |
CRAN checks: | dfmeta results |
Reference manual: | dfmeta.pdf |
Package source: | dfmeta_1.0.0.tar.gz |
Windows binaries: | r-devel: dfmeta_1.0.0.zip, r-release: dfmeta_1.0.0.zip, r-oldrel: dfmeta_1.0.0.zip |
macOS binaries: | r-release (arm64): dfmeta_1.0.0.tgz, r-oldrel (arm64): dfmeta_1.0.0.tgz, r-release (x86_64): dfmeta_1.0.0.tgz, r-oldrel (x86_64): dfmeta_1.0.0.tgz |
Please use the canonical form https://CRAN.R-project.org/package=dfmeta to link to this page.
These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.